{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:19:51Z","timestamp":1791559191746,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012208","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000}}],"reference-count":156,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012208.pub2","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T11:02:49Z","timestamp":1588762969000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration"],"prefix":"10.1002","volume":"2020","author":[{"given":"Emily","family":"Li","sequence":"additional","affiliation":[{"name":"Transitional Year Residency Program; Signature Healthcare Brockton Hospital; Brockton MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Donati","sequence":"additional","affiliation":[{"name":"Department of Surgical and Morphological Sciences, Section of Ophthalmology; University of Insubria, Varese-Como; Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina B","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Life Sciences, Oncology, & Genomics; IBM Watson Health; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena G","family":"Krzystolik","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service; Mass Eye and Ear Infirmary; Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajo.2014.10.005","article-title":"Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration","volume":"159","author":"Barikian","year":"2015","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD012208.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/eye.2013.93","article-title":"Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial)","volume":"27","author":"Menon","year":"2013","journal-title":"Eye"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2014.08.020","article-title":"Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)","volume":"122","author":"Altaweel","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012208.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ceo.12968","article-title":"Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice","volume":"45","author":"Chong","year":"2017","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0006|cit6","first-page":"3154","article-title":"Influence of the vitreomacular interface on treatment outcomes in the Comparison of AMD Treatments Trials (CATT)","volume":"56","author":"Ciulla","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.ophtha.2015.02.031","article-title":"Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"122","author":"Ciulla","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.oret.2016.09.001","article-title":"Visual and morphologic outcomes in eyes with hard exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"1","author":"Daniel","year":"2017","journal-title":"Ophthalmology Retina"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0009|cit9","first-page":"2653","article-title":"Hard exudates and treatment outcomes in the Comparison of Age-related macular degeneration Treatments Trials (CATT)","volume":"57","author":"Daniel","year":"2016","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0010|cit10","first-page":"2833","article-title":"Retinal angiomatous proliferation and treatment outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"56","author":"Daniel","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","article-title":"Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-related macular degeneration Treatments Trials (CATT)","volume":"123","author":"Daniel","year":"2016","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0012|cit12","first-page":"1649","article-title":"Size and growth of geographic atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)","volume":"55","author":"Grunwald","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012208.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the Comparison of Age-related macular degeneration Treatments Trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0015|cit15","first-page":"657","article-title":"Impact of change in retinal thickness on refractive error in the Comparison of Age-related macular degeneration Treatments Trials (CATT)","volume":"55","author":"Huang","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0016|cit16","first-page":"4962","article-title":"Sporadic visual acuity loss in the Comparison of AMD Treatments Trials (CATT)","volume":"55","author":"Kim","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD012208.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0019|cit19","first-page":"1657","article-title":"Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT)","volume":"56","author":"Pistilli","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD012208.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ophtha.2015.11.030","article-title":"Angiographic cystoid macular edema and outcomes in the Comparison of Age-related macular degeneration Treatments Trials","volume":"123","author":"Shah","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012208.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the Comparison of Age-related macular degeneration Treatments Trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/IAE.0000000000000483","article-title":"Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"35","author":"Toth","year":"2015","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD012208.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","article-title":"Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"122","author":"Willoughby","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD012208.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","article-title":"Sustained visual acuity loss in the Comparison of Age-related macular degeneration Treatments Trials","volume":"132","author":"Ying","year":"2014","journal-title":"JAMA Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2015.09.046","article-title":"Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Ying","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.ophtha.2011.02.039","article-title":"Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ajo.2011.08.018","article-title":"Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study","volume":"153","author":"El-Mollayess","year":"2012","journal-title":"American Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.ophtha.2015.03.017","article-title":"Routine versus as-needed bevacizumab with 12-weekly assessment intervals for neovascular age-related macular degeneration: 92-week results of the GMAN Trial","volume":"122","author":"Mahmood","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0032|cit32","first-page":"5358","article-title":"Low luminance vision improves nearly twice as much as standard vision with ranibizumab for neovascular age-related macular degeneration","volume":"56","author":"Frenkel","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"8","key":"10.1002\/14651858.CD012208.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjophthalmol-2015-307575","article-title":"Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision","volume":"100","author":"Frenkel","year":"2016","journal-title":"British Journal of Ophthalmology"},{"issue":"121","key":"10.1002\/14651858.CD012208.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"2014","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0035|cit35","first-page":"5363","article-title":"Improvement in visual acuity following ranibizumab treatment in neovascular age-related macular degeneration patients with large pigment epithelial detachments: a subgroup analysis of the HARBOR study","volume":"56","author":"Khanani","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0036|cit36","first-page":"5362","article-title":"Visual acuity impairment under low luminance conditions at baseline is a powerful predictor of visual acuity response to ranibizumab therapy in patients with neovascular age-related macular degeneration","volume":"56","author":"Penden","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ajo.2015.07.034","article-title":"Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration","volume":"160","author":"Regillo","year":"2015","journal-title":"American Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD012208.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","article-title":"Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR study","volume":"123","author":"Sarraf","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamaophthalmol.2016.0379","article-title":"Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration","volume":"134","author":"Stoller","year":"2016","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technology Assessment"},{"issue":"9900","key":"10.1002\/14651858.CD012208.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"383","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/bjophthalmol-2015-307595","article-title":"Changes in intraocular pressure in study and fellow eyes in the IVAN trial","volume":"100","author":"Foss","year":"2016","journal-title":"British Journal of Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0044|cit44","first-page":"867","article-title":"Visual acuity by responder status in the IVAN clinical trial","volume":"55","author":"Lotery","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1111\/aos.12119","article-title":"Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks","volume":"91","author":"Lushchyk","year":"2013","journal-title":"Acta Ophthalmologica"},{"issue":"10","key":"10.1002\/14651858.CD012208.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.ophtha.2012.05.016","article-title":"Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB). Bevacizumab for neovascular age-related macular degeneration in China","volume":"1119","author":"Li","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD012208.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/IAE.0b013e31828992f5","article-title":"Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy","volume":"33","author":"Sarraf","year":"2013","journal-title":"Retina"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0048|cit48","first-page":"3","article-title":"Ranibizumab 0.5 mg treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: one-year results from the trend study","volume":"58","author":"Mones","year":"2017","journal-title":"Ophthalmic Research"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND Study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0051|cit51","first-page":"5371","article-title":"Multicenter, prospective trial comparing treat & extend to monthly dosing in neovascular AMD management: TREXAMD 12-month outcomes","volume":"56","author":"Wykoff","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD012208.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","article-title":"Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab","volume":"122","author":"Freund","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD012208.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","article-title":"Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid","volume":"123","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0057|cit57","first-page":"3965","article-title":"Baseline characteristics of the fellow eye in patients with wet age-related macular degeneration: post-hoc analysis of the VIEW studies","volume":"55","author":"Korobelnik","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012208.pub2-BIB0058|cit58","first-page":"41","article-title":"Intravitreal aflibercept versus ranibizumab for neovascular age-related macular degeneration: 52-week subgroup analyses from the combined VIEW studies","volume":"40","author":"Mitchell","year":"2012","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3928\/23258160-20160229-06","article-title":"Effect of fluid status at week 12 on visual and anatomic outcomes at week 52 in the VIEW 1 and 2 trials","volume":"47","author":"Moshfeghi","year":"2016","journal-title":"Ophthalmic Surgery Lasers and Imaging Retina"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0060|cit60","first-page":"516","article-title":"Changes in neovascular activity following continuous anti-vascular endothelial growth factor administration in the view studies","volume":"57","author":"Moshfeghi","year":"2016","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/bjophthalmol-2014-305076","article-title":"Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study","volume":"99","author":"Ogura","year":"2015","journal-title":"British Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","article-title":"Scheduled versus pro re nata dosing in the VIEW trials","volume":"122","author":"Richard","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0064|cit64","first-page":"3934","article-title":"Impact of retinal pigment epithelial elevation at baseline on visual outcomes in the view studies","volume":"55","author":"Shah","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0065|cit65","first-page":"868","article-title":"Structure-function correlation of optical coherence tomography features and visual outcome in a fixed and a PRN regimen in neovascular AMD","volume":"55","author":"Simader","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0066|cit66","first-page":"4607","article-title":"Long-term visual outcomes by baseline subgroup characteristics of intravitreal aflibercept injection for neovascular age-related macular degeneration after the VIEW1 study","volume":"56","author":"Singer","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0068|cit68","first-page":"3959","article-title":"Antiangiogenic efficacy of intravitreal aflibercept versus ranibizumab in a fixed and a PRN-guided regimen in the VIEW2 trial","volume":"55","author":"Waldstein","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ophtha.2014.09.024","article-title":"Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration","volume":"122","author":"Yuzawa","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0070|cit70","first-page":"108","article-title":"Baseline characteristics of the fluid study patients: a randomised clinical trial investigating the need for complete resolution of sub-retinal fluid (SRF) in ranibizumab-treated patients with neovascular age-related macular degeneration (NAMD) using a treat and extend (T&E) regimen","volume":"43","author":"Arnold","year":"2015","journal-title":"Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Arnold JJ Markey CM Kurstjens NP Guymer RH The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study BMC Ophthalmology 2016 16 31","DOI":"10.1186\/s12886-016-0207-3"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.ophtha.2015.08.031","article-title":"Re: Berg et al.: comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)","volume":"123","author":"Avery","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2014.10.005","article-title":"Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration","volume":"159","author":"Barikian","year":"2015","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Berg K Hadzalic E Gjertsen I Forsaa V Berger LH Kinge B Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: two-year results Ophthalmology 2016 123 1 51 9","DOI":"10.1016\/j.ophtha.2015.09.018"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0075|cit75","first-page":"1646","article-title":"Randomised controlled trial over 92 weeks using bevacizumab for the treatment of neovascular age-related macular degeneration comparing a treatment regime with 12 weekly regular injections to one with injections on an as-needed basis","volume":"55","author":"Bishop","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Eldem BM Muftuoglu G Topbas S Cakir M Kadayifcilar S Ozmert E A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD Acta Ophthalmologica 2015 93 6 e458 64","DOI":"10.1111\/aos.12540"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Enseleit F Michels S Sudano I Stahel M Zweifel S Schlager O SAVE-AMD: safety of VEGF Inhibitors in age-related macular degeneration Ophthalmologica 2017 238 4 205 16","DOI":"10.1159\/000478665"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1167\/iovs.09-5018","article-title":"Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy","volume":"52","author":"Golbaz","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ophtha.2013.05.032","article-title":"Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration","volume":"120","author":"Mayr-Sponer","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","article-title":"Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration","volume":"121","author":"Simader","year":"2014","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0082|cit82","first-page":"3930","article-title":"Efficacy of intravitreal ranibizumab given bimonthly versus PRN in patients with neovascular age-related macular degeneration: 1 year results of a prospective, randomized clinical trial","volume":"55","author":"Feltgen","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Feltgen N Bertelmann T Bretag M Pfeiffer S Hilgers R Callizo J Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie [Graefe's Archive for Clinical and Experimental Ophthalmology] 2017 255 5 923 34","DOI":"10.1007\/s00417-017-3589-x"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.ophtha.2015.03.017","article-title":"Routine versus as-needed bevacizumab with 12-weekly assessment intervals for neovascular age-related macular degeneration: 92-week results of the GMAN trial","volume":"122","author":"Mahmood","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"Mori R Tanaka K Haruyama M Kawamura A Furuya K Yuzawa M Comparison of pro re nata versus bimonthly injection of intravitreal aflibercept for typical neovascular age-related macular degeneration Ophthalmologica 2017 238 1-2 17 22","DOI":"10.1159\/000468950"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0088|cit88","unstructured":"Gillies M Hunyor A Woodcock C Walsh M Kurstjens N Design and rationale of a clinical trial to measure the development of geographic atrophy in patients undergoing anti-vascular endothelial growth factor treatment for neovascular (WET) age-related macular degeneration: the RIVAL study 46th Annual Scientific Congress of the Royal Australian and New Zealand College of Ophthalmologists; 2014 Nov 22-26; Brisbane, Australia 2014"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3928\/23258160-20130313-04","article-title":"SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results","volume":"44","author":"Wykoff","year":"2013","journal-title":"Ophthalmic Surgery, Lasers & Imaging"},{"issue":"9","key":"10.1002\/14651858.CD012208.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.ophtha.2013.06.030","article-title":"Two year SAVE outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD","volume":"120","author":"Wykoff","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2015.11.002","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study","volume":"162","author":"Brijesh","year":"2016","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000461785","article-title":"One-year outcomes of 1 + pro re nata versus 3 + pro re nata intravitreal aflibercept injection for neovascular age-related macular degeneration","volume":"237","author":"Takayama","year":"2017","journal-title":"Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"A420","DOI":"10.1016\/j.jval.2015.09.554","article-title":"Cost-effectiveness of treatments for wet age-related macular degeneration (WAMD) in the Netherlands, the case of intravitreal aflibercept (IVT-AFL) and ranibizumab","volume":"18","author":"Tempelaar","year":"2015","journal-title":"Value in Health"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","article-title":"Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0095|cit95","first-page":"4620","article-title":"Comparison of aflibercept treatment regimes for treatment resistant neovascular age-related macular degeneration: 8 weekly versus an 'as-needed' regime","volume":"56","author":"Wijeyakumar","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0096|cit96","first-page":"3349","article-title":"Efficacy of retreatments with bevacizumab in choroidal neovascularization","volume":"48","author":"Kon-Jara","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0097|cit97","unstructured":"Airody A Dorey T Mankowska A Balaskas K Mukherjee R Empeslidis T The MATE study: treating neovascular age related macular degeneration with aflibercept: a pilot, 24 month randomised controlled trial comparing standard care with individualised treat and extend regimen Investigative Ophthalmology and Visual Science 2018 59 9 ARVO E abstract 798"},{"issue":"13","key":"10.1002\/14651858.CD012208.pub2-BIB0098|cit98","first-page":"4939","article-title":"Efficacy and cost-effectiveness of anti-VEGF treatments for age-related macular degeneration (AMD)","volume":"55","author":"Nunes","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0099|cit99","unstructured":"Ohnaka M Ohji M Okada A Terano Y Kobayashi M Takahashi K Randomised, open-label study to evaluate 2 intravitreal aflibercept treat-and-extend dosing regimens in wet age-related macular degeneration: 52-week outcomes from ALTAIR 49th Annual Scientific Congress of the Royal Australian and New Zealand College of Ophthalmologists; 2017 Oct 27-Nov 1; Perth, Australia 2017"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-015-0608-2","article-title":"Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial","volume":"16","author":"Foss","year":"2015","journal-title":"Trials"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0101|cit101","unstructured":"Age-related macular degeneration eyewiki.aao.org\/Age-related_macular_degeneration"},{"issue":"8","key":"10.1002\/14651858.CD012208.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/IAE.0000000000000134","article-title":"Anti-VEGF treatment in neovascular age-related macular degeneration","volume":"34","author":"Abedi","year":"2014","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/aos.13522","article-title":"An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration","volume":"95","author":"Berg","year":"2017","journal-title":"Acta Ophthalmologica"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bjophthalmol-2013-304033","article-title":"Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010","volume":"98","author":"Bourne","year":"2014","journal-title":"British Journal of Ophthalmology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD012208.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0107|cit107","first-page":"173","article-title":"The burden of age-related macular degeneration: a value-based medicine analysis","volume":"103","author":"Brown","year":"2005","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0108|cit108","first-page":"257","article-title":"The burden of age-related macular degeneration: a value-based analysis","volume":"17","author":"Brown","year":"2006","journal-title":"Current Opinion in Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.icu.0000120710.35941.3f","article-title":"Age-related macular degeneration and depression: a review of recent research","volume":"15","author":"Casten","year":"2004","journal-title":"Current Opinion in Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","article-title":"A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration","volume":"100","author":"Chin-Yee","year":"2016","journal-title":"British Journal of Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD012208.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.1996.03540140035023","article-title":"A prospective study of cigarette smoking and risk of age-related macular degeneration in men","volume":"276","author":"Christen","year":"1996","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0114|cit114","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/bjo.2004.049726","article-title":"28,000 cases of age-related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking","volume":"89","author":"Evans","year":"2005","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012208.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev.clinpsy.032408.153621","article-title":"Depression in older adults","volume":"5","author":"Fiske","year":"2009","journal-title":"Annual Review of Clinical Psychology"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.02.048","article-title":"Risk factors for conversion to neovascular age-related macular degeneration based on longitudinal morphologic and visual acuity data","volume":"119","author":"Friberg","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0161-6420(99)90267-1","article-title":"Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey","volume":"106","author":"Friedman","year":"1999","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012208.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD012208.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL non-inferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0123|cit123","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0124|cit124","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"12","key":"10.1002\/14651858.CD012208.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4172\/1948-5956.1000235","article-title":"Regulation of tumor angiogenesis and choroidal neovascularization by endogenous angioinhibitors","volume":"5","author":"Gunda","year":"2013","journal-title":"Journal of Cancer Science and Therapy"},{"issue":"11","key":"10.1002\/14651858.CD012208.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0127|cit127","first-page":"47","volume-title":"Basic Ophthalmology","author":"Harper","year":"2010"},{"issue":"11","key":"10.1002\/14651858.CD012208.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"issue":"7","key":"10.1002\/14651858.CD012208.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD012208.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0161-6420(92)31871-8","article-title":"Prevalence of age-related maculopathy. The Beaver Dam Eye Study","volume":"99","author":"Klein","year":"1992","journal-title":"Ophthalmology"},{"issue":"Suppl","key":"10.1002\/14651858.CD012208.pub2-BIB0133|cit133","first-page":"335","article-title":"The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975","volume":"24","author":"Leibowitz","year":"1980","journal-title":"Survey of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"British Journal of Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD012208.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2012.10.018","article-title":"Age-related macular degeneration revisited - piecing the puzzle: the LXIX Edward Jackson memorial lecture","volume":"155","author":"Miller","year":"2013","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD012208.pub2-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","author":"Moja","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0138|cit138","unstructured":"National Eye Institute National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25), 2000 nei.nih.gov\/sites\/default\/files\/nei-pdfs\/vfq_sa.pdf"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0141|cit141","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011346.pub2","article-title":"Aflibercept for neovascular age-related macular degeneration","author":"Sarwar","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD012208.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"e0137866","DOI":"10.1371\/journal.pone.0137866","article-title":"Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Schmucker","year":"2015","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.CD012208.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ophtha.2012.07.026","article-title":"The SECURE Study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration","volume":"120","author":"Silva","year":"2013","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD012208.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.1996.03540140029022","article-title":"A prospective study of cigarette smoking and age-related macular degeneration in women","volume":"276","author":"Seddon","year":"1996","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD012208.pub2-BIB0147|cit147","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub3","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012208.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"issue":"R2","key":"10.1002\/14651858.CD012208.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1093\/hmg\/ddm212","article-title":"Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits","volume":"16","author":"Swaroop","year":"2007","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0150|cit150","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2","volume":"119","author":"Bressler","year":"2001","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2","volume":"131","author":"Verteporfin In Photodynamic (VIP) Therapy Study Group","year":"2001","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD012208.pub2-BIB0152|cit152","first-page":"1508.e1","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","author":"Chakravarthy","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012208.pub2-BIB0153|cit153","unstructured":"World Health Organization Causes of blindness and visual impairment www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment"},{"issue":"3","key":"10.1002\/14651858.CD012208.pub2-BIB0154|cit154","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002030.pub3","article-title":"Photodynamic therapy for neovascular age-related macular degeneration","author":"Wormald","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012208.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/jcm4020343","article-title":"Age-related macular degeneration: advances in management and diagnosis","volume":"4","author":"Yonekawa","year":"2015","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012208.pub2-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012208","article-title":"Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","author":"Li","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T10:32:29Z","timestamp":1702895549000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012208.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":156,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012208.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]}}}